ArticleTranslational cancer research2025
tRF-29-86J8WPMN1EJ3: a tRNA-derived small RNA promoting esophageal cancer progression.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transfer RNA-derived small RNAs (tsRNAs) have been shown to participate in tumorigenesis and progression of human cancers. We aimed to identify dysregulated tsRNAs in esophageal cancer (EC) and uncover the underlying mechanisms. Methods: tsRNA profiles for EC were downloaded from MINTbase. We also detected expression levels of tsRNAs in EC tissues using tsRNA sequencing and real-time quantitative polymerase chain reaction (RT-qPCR). The functional roles of tRF-29-86J8WPMN1EJ3 in EC were investigated by transfecting EC cell lines with mimics of tRF-29-86J8WPMN1EJ3 and assessing phenotypes through colony formation, wound healing, and Transwell assays. Results: Totally, 210 differentially expressed tsRNAs were identified from MINTbase. In addition, 40 EC patients were recruited, and four paired EC and adjacent normal tissues were randomly selected for tsRNA sequencing, identifying 159 dysregulated tsRNAs, which were intersected with the 210 tsRNAs from MINTbase, obtaining three tsRNAs: tRF-28-P4R8YP9LOND5, tRF-29-86J8WPMN1EJ3, and tRF-29-P4R8YP9LONHK. Their expression levels were validated in 40 paired tissues. All three tsRNAs were up-regulated in EC tissues, and their high expression levels were associated with shorter overall survival (OS) in EC patients. Conclusions: In conclusion, we presented the expression characteristics of tsRNAs in EC and identified three up-regulated tsRNAs in EC tissues. Lower expression levels of these tsRNAs were associated with better OS in EC patients. Additionally, tRF-29-86J8WPMN1EJ3 promotes the proliferation, migration, and invasion of EC cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.